Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Leo Miller

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are two weight-loss and diabetes drug stocks that have been on completely different trajectories. Since the start of 2025, LLY is up nearly 30%, while NVO has plummeted more than 30%.

This comes as Eli Lilly has taken massive market share from Novo. In its latest quarter, Eli Lilly posted revenue growth of 56% year over year (YOY). For the full-year 2026, the midpoint of Lilly’s guidance implies growth of 28% YOY.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.